Press Releases | Regeneron Pharmaceuticals Inc.
WEBLibtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer. Sep 9. Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO. Aug 26.
Dupixent® (dupilumab) Approved in the U.S. as First and Only …
WEB6 days ago · TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic ...
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at …
WEBTARRYTOWN, N.Y., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced five-year results from the final pre-specified overall survival (OS) analysis of the Phase 3 EMPOWER-Lung 1 trial, which evaluated Libtayo ® (cemiplimab) monotherapy versus chemotherapy as a …
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
WEB2 days ago · The latest approval expands the initial FDA approval (granted in June 2019) in CRSwNP for patients aged 18 years and older. Regeneron’s shares have rallied 31.3% year to date compared to the ...
News Release - Regeneron Pharmaceuticals Inc.
WEBAug 1, 2024 · Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and complementary approaches to potentially treat or cure diseases.
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBMar 23, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567).
Regeneron Announces New U.S. Government Agreement to …
WEBUnder the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022, at a cost of $2,100 per dose. This new agreement follows two earlier agreements with the U.S. government announced in July 2020 and January 2021.
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 · Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline. TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization ...
Buy Rating Affirmed: Regeneron’s Growth Potential Anchored by …
WEB2 days ago · Additionally, Regeneron’s strategic moves to expand its oncology offerings, including bispecific antibodies and the recent acquisition of assets from 2seventy, contribute to the optimistic outlook.
Analyst Issues Sell Rating for Regeneron Amid Competitive …
WEB2 days ago · Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various ...